Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.375 5.26% 7.50 7.25 7.75 7.50 6.75 7.13 554,119 16:09:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 16

Eden Research Share Discussion Threads

Showing 7051 to 7073 of 8325 messages
Chat Pages: Latest  285  284  283  282  281  280  279  278  277  276  275  274  Older
DateSubjectAuthorDiscuss
14/5/2019
14:02
Addressable ' future ' market updated to 4bn. But what does that mean? Eg. How does it differ from 'tomorrow'? Sorry to be pernickety. !!!!!!
brucie5
14/5/2019
13:51
AGM Presentation - hTTp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/agm-presentation-2019.pdf
wan
14/5/2019
08:51
It will be interesting to see if the "emergency use" authorisation in Italy for Mevalone addressing Botrytis on kiwifruit (not reported by Eden, but highlighted in post 409) eventually gets cited. Because as per the Cedroz emergency authorisation, it also implies the lack of a suitable alternative, highlights the proven efficacy provided by Mevalone and indeed highlights the significance of the kiwifruit market! hTTp://www.sipcamitalia.it/it/fungicidi/25/3logy/X/16396 kiwifruit represents a sizeable and important market in Italy, and Italy are the global number two exporter of kiwifruit - Kiwifruit Exports by Country JULY 10, 2018 BY DANIEL WORKMAN Below are the 15 countries that exported the highest dollar value worth of kiwifruit during 2017. 1. New Zealand: US$1.2 billion (43.6% of total kiwifruit exports) 2. Italy: $527.6 million (19.5%) 3. Belgium: $329.6 million (12.2%) 4. Chile: $188 million (6.9%) 5. Greece: $130.6 million (4.8%) hTTp://www.worldstopexports.com/kiwifruit-exports-by-country/
wan
14/5/2019
08:45
Old rhetoric Super. Possibly Investing, but in a rapidly evolving paradigm where the untouchables are getting their Hubris trashed and reputation publicly savaged, where the SustainabilityMegaTrend is being kicked up a gear or two, the statement and more importantly the products/technology has way more currency. Eden's time has come ...as you can see by the volume of trades today:)
supersonico
14/5/2019
08:37
Yes, major question is how they intend to effect the 'strategic change' that Wan speaks of. They have intimated they intend to bring in more staff: but this will require extra spend. So how will they do this without a further RI?
brucie5
14/5/2019
08:30
Oh dear! If they don’t indicate today how they ate going to immediately go into overdrive they will surely miss out. They have access to whatever Sipcam know from their lab but not the capability or personnel to exploit it or understand it. If they are not careful they will be superseded by all the competition just as Eastman stole a march on Sipcam in the short term
chrischas
14/5/2019
08:24
“No new material will be disclosed in the presentation” from today’s AGM statement. You have to ask ......what the point of Sean presenting it is then.
ipeesquint
14/5/2019
08:12
Clearly, Eden's expanding "footprint" will be a key driver going forwards, but I am still 'very' optimistic about label extensions to cover major new disease and other crop targets. For which Sipcam, the "exclusive" distributor, is obviously optimistic too in this regard ;-)
wan
14/5/2019
06:27
Old rhetoric Super. I hope they're delivering a lot more than that today.
investingisatrickygame
14/5/2019
06:09
hTTps://www.investegate.co.uk/eden-research-plc--eden-/rns/agm-statement/201905140700048845Y/ It is clear that the world of agchem, whilst inherently conservative, is swiftly undergoing major disruption due to external drivers such as regulatory issues, resistance problems with conventional pesticides, and the ever-increasing cost of the registration of new products. In this environment of turmoil and disruption caused by the removal of important conventional pesticides from global markets at a rate that is troubling for farmers, Eden is well-placed to sustainably and effectively meet many of the current and future needs of growers. Eden's products align perfectly with the course set for the industry by changing public policy and increasingly challenging regulations, and we aim to ensure that the Company, our shareholders, growers and our commercial partners benefit from the success that this alignment will bring."
supersonico
13/5/2019
21:38
BREAKING: Monsanto Hit With $2B Verdict In 3rd Roundup Trial hTTps://www.law360.com/articles/1158218/breaking-monsanto-hit-with-2b-verdict-in-3rd-roundup-trial
supersonico
13/5/2019
21:08
I look forward to daily rises here of the likes seen on IOF currently; you wait an eternity for a bus and then several come along all at the same time. Likewise JPL. You know what it is when it happens because the story comes together and there is serious interest from stake holders and clear exposition by the CEO. We may not be so far away. But I am curious to see what leadership and clarity is offered tomorrow. Thanks Sortudo, and please do not hold back from the hard ball questions.
brucie5
13/5/2019
19:25
Brucie, I have a lot of questions to ask but I'm not sure if they will be all answered. Questions such as: TT/Bayer, Biocides, why they (BoD) have increased their own salaries while the share price hasn't moved up?, Sipcan/Eastman/Sustaine-progress, Lykele's short order and no investment in the company, Are they happy with Eden's PR team? 3aey stage, etc, etc.
sortudo7
13/5/2019
16:56
Another delayed trade posted today of 250,000 shares from 10/5.
investingisatrickygame
13/5/2019
16:52
Hope all who attend tomorrow's AGM have the time to post their thoughts. Any further feedback on cedroz will be appreciated. To me this is the most significant product to date. With up to four season a year for the greenhouse vegetables we have a product that takes away seasonality at a stroke. As outside weather conditions are unlikely to impact nasty nematodes in greenhouse, cedroz sales will not be impacted by weather conditions like 3AEY has suffered these past two years. Furthermore with growers hearing of the benefit / efficacy of cedroz there are up to four times a year to increase market share. Eastman is much more a brand developer than Sipcam. I am confident we can look forward to great success with cedroz. It would be good if the BoD expressed similar views!
attyg
13/5/2019
16:12
Don’t you think it’s strange and funny that Eastman make the first sales of Cedroz in Sipcams’backyard.?
chrischas
13/5/2019
15:29
Supersonico, they do need to be more exacting in their delivery of message. In short order as you say is not one whole year! So what did short order mean to him and why has it not transpired? Why has his investment in Eden Research still not materialised? What stage of development are we with new products coming on board that he has suggested will be bigger than Cedroz? Why has the Company not given us one single progress report on Sipcam's evaluation of Sustaine across (19?) products? Please tell us what progress has been made with the encapsulation of their chemistries based products and what progress has been made with the inclusion of our active ingredients for co-encapsulation of their products? Are these near term operations? Will they have a material effect on Eden's revenues and market acceptance, offerings and positioning in the crop protection industry. If yes, please explain in some detail. It is crazy that Sipcam has been evaluating Sustaine for 2 years and not one progress report at all. A positive progress report would build momentum into the narrative and the share price, gaining at each step when an update is issued. Eden is far too quiet to justify an investment, providing no value direction and no call to action from their audience. Hence a totally stifled share price. It is more than reasonable to expect this line of questioning to be answered rather than another year of minimal information feed.
investingisatrickygame
13/5/2019
14:04
Clearly for Lykele something changed during this year just gone that effected his estimations. His 'short order' replaced the 'in the coming months' carrots. I believe he expected TT and Bayer action before now but it has not materialised and I'm yet to be convinced it will happen in the coming September. IMO he needs to explain as clearly as he is able within the limits of the NDA's what he expected and what has changed without pulling our collective formulation/ shelf life/ back to sKool chain any longer. . They are simply not reputationally credible or cohesive on these areas of the business as the narrative currently stands.
supersonico
13/5/2019
13:05
On an aside I listened to what my wife was watching on the box.Dragons den!! All the investors dropped a good product because the management showed no short term ambition. I was on my computer in the next room and came in to watch and immediately thought of my stake in Eden!!! Not sure why I am smiling.
chrischas
13/5/2019
12:38
But is that a question? (Without doubting its pertinacity!)
brucie5
13/5/2019
11:32
Question? As the Market for chemical treatment has and is radically changed/ changing right now ,my question would be the following. How is the BOD reacting to the change before their eyes? Surely this year they should be much more proactive and hire on people who can spread their news? No more talking of medium term ambitions.In short get out and sell the bloody stuffL
chrischas
13/5/2019
11:20
Sadly I cannot make it. I am most surprised and disappointed you have been told you are unable to attend. That would be a departure from all previous AGMs and a sad departure. Eden is a growth story/share and as such always has been welcoming of people who make the effort to learn more about the company. I recommend you email either Alex or Sean and explain your position. I would be surprised if they did not allow you to join the meeting. I am disappointed by the progress announced through RNSs and the results, and of course lykele's reluctance to follow his fellow directors by putting his hand in his pocket - something which he alone is in control of yet manages to side step. I am, however, even more encouraged by eastman's performance and am confident cedroz will deliver this year and increasingly so in the years ahead. The market cap of this company is woeful and is a huge discount to the true value. I guess we require to see more evidence of commercial take up before the market sees Eden for what it is/can become.
attyg
13/5/2019
10:39
Thanks Atty. I have just been advised that I cannot. :( Mea culpa. But I dare say my curiosity will be well represented by others far more knowledgeable about the right questions to ask. I was most appreciative of your feedback last year, including the impressions you drew in relation to the candour and optimism of new chair. Perhaps some of those impressions have been disappointed? May I assume you'll be there again to follow up?
brucie5
Chat Pages: Latest  285  284  283  282  281  280  279  278  277  276  275  274  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191207 03:49:25